Ki-67 labeling index as a prognostic marker in advanced stomach cancer.
10.4174/astr.2019.96.1.27
- Author:
Sang Hyuk SEO
1
;
Kwang Hee KIM
;
Sang Hoon OH
;
Yunseon CHOI
;
Ki Jung AHN
;
Ji Young LEE
;
Sang Min LEE
;
Jisun PARK
;
Woo Gyeong KIM
Author Information
1. Department of Surgery, Inje University Busan Paik Hospital, Busan, Korea.
- Publication Type:Original Article
- Keywords:
Stomach neoplasms;
Ki-67;
Survival;
Prognosis
- MeSH:
Chemotherapy, Adjuvant;
Disease-Free Survival;
Follow-Up Studies;
Humans;
Ki-67 Antigen;
Lymph Nodes;
Neoplasm Metastasis;
Neurons;
Prognosis;
Recurrence;
Retrospective Studies;
Stomach Neoplasms*;
Stomach*
- From:Annals of Surgical Treatment and Research
2019;96(1):27-33
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: Proliferation marker Ki-67 is widely used in cancer prognosis prediction. We tried to investigate the role of Ki-67 as a prognostic factor in stomach cancer after surgery in this study. METHODS: We retrospectively evaluated 251 patients who underwent curative resection for gastric cancer from 2010 to 2015. In pathologic examination, Ki-67 labeling index was defined as the percentage of Ki-67 antigen positive cells. Prognostic significance of Ki-67 for gastric cancer was evaluated. Disease-free survival (DFS) was assessed as a primary end-point. RESULTS: The median follow-up period was 28.0 months. Thirty-one patients (12.4%) showed Ki-67 labeling index (LI) lower than 25%. Sixty-eight patients (26.6%) showed recurrence during follow-up period. Recurrence was associated with Ki-67 LI level (≤25%, P = 0.016), and lymph node metastasis status (P = 0.002). High Ki-67 LI level (>25%) was also related to p53 positivity (P < 0.001) and poorly cohesive type (P = 0.002). The 3-year DFS was 69.4%. Low Ki-67 LI level (≤25%) was related with low DFS (47.6% vs. 72.6%, P = 0.016). T stage (P < 0.001), N stage (P = 0.006), lymphovascular invasion (P = 0.010), and neuronal invasion (P = 0.001) also affected the DFS. In addition, T stage (P = 0.03) and Ki-67 LI (P = 0.035) were independent prognostic factors for DFS. In patients treated with adjuvant chemotherapy (n = 239, 93.4%), low Ki-67 (≤25%) was a poor prognostic factor for DFS (P = 0.013). CONCLUSION: Low Ki-67 LI predicts high rate of progression and low DFS of stomach cancer. Ki-67 LI can be a predictive marker in resected stomach cancer treated with surgery and adjuvant chemotherapy.
